Stocks in play: BriaCell Therapeutics Corp

Announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty member. The research collaboration will focus on the discovery and development of novel targets to enhance tumor cell responsiveness to chemotherapy and immunotherapies in specific cancers including lung, head and neck, cervical, and bladder cancers. BriaCell Therapeutics Corp shares T.BCT are trading up $0.03 at $8.08.

Read:

• Innovative Food Stocks Responding to Conflict-, and Drought-Driven Food Supply Shocks

• Crypto Miners Finding Success While Shifting Towards Environmentally Sustainable Operations

• New Approaches Towards Immunotherapy Give Hope in Fight Against Solid Tumors

• As a Major Social Media Shuffle Looms, Uptake and Value of Dogecoin (DOGE) Surges

• New Regions Being Developed to Produce More Oil Amid Government’s Calls for More Output